4//SEC Filing
Aralez Pharmaceuticals Inc. 4
Accession 0001104659-16-095172
CIK 0001660719operating
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 9:43 PM ET
Size
29.2 KB
Accession
0001104659-16-095172
Insider Transaction Report
Form 4
BARNHARDT JOHN E
VP, Finance and Administration
Transactions
- Other
Stock Option (Right to Buy)
2016-02-05+41,195→ 41,195 totalExercise: $13.84Exp: 2017-01-03→ Common Shares (41,195 underlying) - Other
Stock Option (Right to Buy)
2016-02-05+14,658→ 14,658 totalExercise: $8.36Exp: 2018-03-14→ Common Shares (14,658 underlying) - Other
Stock Option (Right to Buy)
2016-02-05+15,757→ 15,757 totalExercise: $11.83Exp: 2018-05-06→ Common Shares (15,757 underlying) - Other
Common Shares
2016-02-05+75,528→ 75,528 total - Other
Stock Option (right to buy)
2016-02-05+9,161→ 9,161 totalExercise: $3.87Exp: 2022-03-15→ Common Shares (9,161 underlying)
Footnotes (5)
- [F1]Reflects the beneficial ownership of the reporting person following consummation of the business transaction among POZEN Inc. ("Pozen"), Tribute Pharmaceuticals Canada Inc. ("Tribute") and the Registrant on February 5, 2016, pursuant to the Agreement and Plan of Merger and Arrangement as entered into on June 8, 2015 and as amended on August 19, 2015 and December 7, 2015 among Pozen, Tribute, the Registrant, Aralez Pharmaceuticals Holdings Limited, ARLZ US Acquisition II Corp., and ARLZ CA Acquisition Corp. (the "Merger").
- [F2]The option vested in four equal annual installments, with the initial vesting date occurring on January 3, 2008.
- [F3]The option vested in four equal annual installments, with the initial vesting date occurring March 14, 2009.
- [F4]The options vested as follows: twenty-five percent (25%) vested upon the acceptance by the U.S. Food and Drug Administration (FDA) of the New Drug Application (NDA) for PN 400; the remaining seventy-five (75%) vested upon the receipt by the Company of an action letter from the FDA indicating approval of the NDA for PN 400. The options also include provisions that required satisfactory employee performance prior to vesting.
- [F5]The options vested as follows: fifty percent (50%) on the third anniversary of the date of grant, and fifty percent (50%) on February 5, 2016.
Documents
Issuer
Aralez Pharmaceuticals Inc.
CIK 0001660719
Entity typeoperating
IncorporatedBritish Columbia, Canada
Related Parties
1- filerCIK 0001660719
Filing Metadata
- Form type
- 4
- Filed
- Feb 8, 7:00 PM ET
- Accepted
- Feb 9, 9:43 PM ET
- Size
- 29.2 KB